Versant Capital Management’s Citius Oncology CTOR Stock Holding History

Versant Capital Management’s Portfolio CTOR Stock Details CTOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,500	Closed	-$1.5K	–	2858
2025 Q4	$1.5K	Buy	+1,500	New	+$2.15K	﹤0.01%	2482

Other funds holding CTOR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Versant Capital Management's CTOR Position: Q1 2026 in Review

Versant Capital Management sold out of Citius Oncology (CTOR) in Q1 2026, closing a stake of 1,500 shares — an estimated $1.5K sold.

Versant Capital Management first reported a position in CTOR in Q4 2025 and held it in 1 quarter. The position peaked at $1.5K in Q4 2025. 14 funds tracked by Wall St. Rank hold CTOR as of Q1 2026.

Versant Capital Management reported no remaining Citius Oncology position as of Q1 2026 after selling out during the quarter.
Versant Capital Management sold 1,500 Citius Oncology shares in Q1 2026, an estimated $1.5K.
Versant Capital Management first reported a position in Citius Oncology in Q4 2025 and held it in 1 quarter.
Versant Capital Management's Citius Oncology position peaked at $1.5K in Q4 2025.
14 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2026.

Based on Versant Capital Management's 13F filing for Q1 2026, filed 7 Apr 2026.